NEET PG Medical – 2019 – Question – 89
MOA of Teduglutide in short bowel syndrome?
a) GLP-2 inhibitor
b) HT1a inhibitor
c) GLP-1 analogs
d) C-peptide analogs
Show Answer
Correct Answer – A
Ans. A. GLP-2 inhibitor
Glucagon-like peptide-2 (GLP-2) – Important intestinotrophic growth factor & mediator of intestinal adaptation.
FDA approved teduglutide (Gattex—NPS) to treat short bowel syndrome in adult patients requiring additional nutrition from I.V. parenteral nutrition.
Effectively improves fluid absorption.
